# Phase 2/Phase 3 Study To Evaluate The Efficacy And Safety Of Ramatroban Along With The Standard Of Care In Subjects Hospitalized For COVID Pneumonia

> **NCT05706454** · PHASE2,PHASE3 · RECRUITING · sponsor: **KARE Biosciences** · enrollment: 324 (estimated)

## Conditions studied

- COVID-19 Pneumonia
- COVID-19 Respiratory Infection

## Interventions

- **DRUG:** Ramatroban
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05706454
- **Lead sponsor:** KARE Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-10
- **Primary completion:** 2024-07-01
- **Final completion:** 2026-05-31
- **Target enrollment:** 324 (ESTIMATED)
- **Last updated:** 2023-01-31

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05706454

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05706454, "Phase 2/Phase 3 Study To Evaluate The Efficacy And Safety Of Ramatroban Along With The Standard Of Care In Subjects Hospitalized For COVID Pneumonia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05706454. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*